In a landmark judgment, the Delhi High Court has ruled that Novo Nordisk failed to prove why it should be granted an interim injunction against Dr. Reddy’s, but has ordered the latter not to proceed with sales in Indian until the patent-in-suit expires on March 20, 2026.